Halometasone, the first new drug of Huabang pharmaceutical, will be approved soon

According to the website of the State Food and Drug Administration (CFDA) on May 15, the status of Halometasone, a new drug for external use of Huabang pharmaceutical, has changed to "under approval", which means that the drug has passed the technical review and production site inspection and entered the final approval stage It is expected to obtain the production approval document in about three months Company insiders said no approval had been received He said that every year, the company will have new drugs approved Now, there is no plan for the production and sales of halometason, which will be put into the market when the time is right Halometasone is used in the skin diseases that respond to corticosteroids Local application has rapid anti-inflammatory, anti allergic, antipruritic, anti exudative and anti proliferative effects At the same time of applying for Halometasone, Huabang Yingtai also applied for Halometasone Cream At present, there is no enterprise in China to produce Halometasone Cream Huabang Yingtai is expected to become the first Chinese imitation of the drug According to the public information, the original research enterprise of halometason is Novartis, Switzerland In addition to Novartis, domestic imported drugs also include Australian energy produced by Australia and the United States (Hong Kong, China) Huabang pharmaceutical's skin disease drugs and tuberculosis drugs occupy a leading position in the domestic market After cooperating with Parkson pharmaceutical to expand new sales channels such as e-commerce, it is expected to open a wider sales space According to the annual report data, in 2014, the company achieved an operating revenue of 4.867 billion yuan, a year-on-year increase of 9.0%; the net profit attributable to the parent company was 429 million yuan, a year-on-year increase of 41.8%.